JDC clears two critical EW-001 milestones ahead of November FDA meeting
AdAlta Limited (ASX: 1AD) has announced that the Joint Development Committee (JDC) for its lead CAR-T cell therapy EW-001 formally approved two mandatory next steps at its late September 2026 meeting in Shanghai. The JDC, which brings AdAlta together with Shanghai Cell Therapy Group (SHcell), approved both the FDA briefing pack and the EW-001 manufacturing technology transfer plan to Cell Therapies Pty Ltd (CTPL) in Melbourne. Both are formal governance requirements under the parties’ Development and Collaboration Agreement, and their approval clears the path for AdAlta’s pre-IND meeting with the US Food and Drug Administration (FDA) scheduled for 3 November 2026 US time (4 November 2026 AEST).
When big ASX news breaks, our subscribers know first
What the JDC approved and why it matters
FDA briefing pack submission
Before a pre-IND meeting, the FDA reviews a detailed briefing pack covering how EW-001 is made and tested, the known safety and efficacy profile, and the proposed Phase 1 clinical trial design. Because much of this data originates from SHcell, the JDC’s formal approval confirms that both partners stand behind the proposals and information being presented to the FDA — a significant commercial alignment signal ahead of a critical regulatory engagement.
The briefing pack has been submitted on schedule. The FDA generally issues formal written minutes two to four weeks after the meeting, and AdAlta has indicated it will update the market accordingly.
Manufacturing technology transfer to Australia
The JDC also approved the plan to transfer SHcell’s rapid, low-cost third-generation EW-001 manufacturing process, including its testing methods and know-how, to CTPL in Melbourne. Manufacturing EW-001 in Australia to FDA standards is an essential regulatory prerequisite before Phase 1 clinical trials can begin. First Australian manufacturing runs are anticipated in the second half of calendar 2026.
The CTPL manufacturing agreement signed in April 2026 established the Australian facility as AdAlta’s intended global reference site, with the 2-day EW-001 manufacturing process offering a significant speed and cost advantage over the 9-day standard for conventional CAR-T therapies.
Dr Tim Oldham, CEO and Managing Director, AdAlta
“These are the approvals we needed to take EW-001 to its next stage. SHcell has endorsed both what we will discuss with the FDA in November and how EW-001 will be made in Melbourne, so we can now move ahead with both.”
Understanding EW-001 and why mesothelioma matters to investors
CAR-T cell therapy is a form of cellular immunotherapy in which a patient’s own immune cells are engineered in a laboratory to find and kill cancer cells. The therapy is manufactured from a patient’s own cells and administered as a single treatment, with the potential to deliver durable cancer control.
Mesothelioma is a rare but rapidly fatal cancer most commonly linked to asbestos exposure. Once a patient relapses after initial treatment, second-line options are extremely limited and outcomes are significantly worse. The contrast between current standard-of-care results and the early EW-001 data from investigator-initiated trials (IITs) in China is material.
| Metric | Standard of Care (1st line) | Standard of Care (2nd line+) | EW-001 China IIT Results |
|---|---|---|---|
| Overall Response Rate | 40–44% | 11–29% | Up to 50% |
| Complete Response Rate | <3% | Rare/almost never | Up to 20% |
| Median Overall Survival | 14–18 months | 8–10 months | Not yet reached (earlier generation: >25 months) |
These early results suggest EW-001 may offer a potential new treatment option for patients with very limited alternatives. EW-001 has not yet received regulatory approval for general commercial launch anywhere in the world.
Beyond mesothelioma, EW-001 targets mesothelin, a protein highly expressed in more than ten cancer types. The broader cellular immunotherapy market is projected to reach US$20.3 billion by 2028, growing at a compound annual growth rate of 34%.
Patient update from China and the road to Australian trials
Two patients remain on study
In July 2026, AdAlta reported that all five patients then remaining in SHcell’s IITs of EW-001 in China were alive. Further details are now available on each:
- Patient 1: Achieved a complete response and completed the study at the two-year mark, with no evidence of cancer returning
- Patients 2–3: Progressive disease confirmed; withdrawn from formal follow-up per protocol, having previously achieved a partial response and stable disease respectively
- Patient 4: The second complete responder, who has passed one year of survival and is next due for formal assessment at 18 months
- Patient 5: Stable disease confirmed at the six-month assessment; remains on study
The next formal assessments for both patients currently on study are expected in the first quarter of calendar 2027. No patients have yet been treated under the Hainan Boao Lecheng special access approval announced in September 2026.
What comes next
The near-term catalyst sequence for investors to monitor is as follows:
- FDA pre-IND meeting — 4 November 2026 AEST
- FDA written minutes — expected two to four weeks post-meeting
- Manufacturing technology transfer to CTPL — underway, with first Australian runs targeted in the second half of calendar 2026
- China patient follow-up assessments — first quarter of calendar 2027
Both partners have now formally agreed on what will be presented to the FDA and on how EW-001 will be manufactured in Australia — the two foundations required for AdAlta’s planned Phase 1 clinical trials.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who never miss a market-moving announcement. Click the “Free Alerts” button at StockWire X to get real-time alerts the moment news breaks.